Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
113 hedge funds and large institutions have $551M invested in Accelerate Diagnostics in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 19 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
7% less call options, than puts
Call options by funds: $9.5M | Put options by funds: $10.2M
3% less funds holding
Funds holding: 117 → 113 (-4)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
19% less capital invested
Capital invested by funds: $679M → $551M (-$127M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Chicago Capital
Chicago,
Illinois
|
+$6.48M |
| 2 |
GAM
Griffin Asset Management
New York
|
+$5.12M |
| 3 |
Morgan Stanley
New York
|
+$2.01M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.49M |
| 5 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.91M |
| 2 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$5.49M |
| 3 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
-$3.46M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$2.59M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$2.13M |
AXDX Hedge Fund Activity: Q3 2019 in Review
113 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2019, worth a combined $551M — down 19% from $679M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AXDX and 16 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 33 added.
The largest buyer was Chicago Capital, adding an estimated $6.48M. The largest seller was Credit Suisse, cutting an estimated $5.91M.
- 113 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2019, down from 117 in Q2 2019.
- Funds reported $551M of Accelerate Diagnostics stock for Q3 2019, down 19% quarter-over-quarter.
- 16 funds opened new Accelerate Diagnostics positions in Q3 2019 and 19 closed out, a net change of -3 holders.
- The largest Accelerate Diagnostics buyer in Q3 2019 was Chicago Capital, an estimated $6.48M added.
- The largest Accelerate Diagnostics seller in Q3 2019 was Credit Suisse, an estimated $5.91M sold.
Based on aggregated 13F filings for Q3 2019.